Latest news with #Ranibizumab
The Hindu
12-08-2025
- Business
- The Hindu
Sandoz to market Lupin's biosimilar ranibizumab in multiple markets globally
Lupin on Tuesday announced a partnership with Swiss major Sandoz Group AG to market and commercialise its biosimilar ranibizumab across multiple regions. Sandoz will oversee commercialisation of the product across European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Ranibizumab is indicated in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR) and Choroidal Neovascularization (CNV). Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. It will also acquire sole rights for commercialisation of the biosimilar in Canada, while Lupin will manage the manufacture and regulatory filings.
Business Standard
12-08-2025
- Business
- Business Standard
Lupin joins hands with Sandoz to commercialize biosimilar Ranibizumab across multiple regions
Lupin has announced a strategic partnership with Switzerland-based Sandoz Group AG (Sandoz) to market and commercialize its biosimilar ranibizumab across multiple regions. Under the agreement, Sandoz will handle commercialization of the biosimilar across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and managing regulatory submissions. In most designated markets, Sandoz will have exclusive marketing rights, while in France, Australia, Vietnam, and Malaysia, the rights will be semi-exclusive. Additionally, through a separate agreement, Sandoz will acquire sole commercialization rights for Lupins biosimilar ranibizumab in Canada, with Lupin continuing to manage manufacturing and regulatory filings. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV). Thierry Volle, President EMEA and Emerging Markets, Lupin, said, We are delighted to partner with Sandoz for the launch and commercialization of ranibizumab in multiple markets globally. This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupins consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25. The counter rose 0.45% to Rs 1,955 on the BSE.
Business Standard
12-08-2025
- Business
- Business Standard
Lupin partners with Sandoz for launch and commercialization of ranibizumab across global markets
Lupin today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin's biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and for regulatory submissions. Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin's biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV).
News18
12-08-2025
- Business
- News18
Lupin ties up with Sandoz to commercialise biosimilar product
Agency: PTI Last Updated: New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement. Lupin will be responsible for manufacturing the product and for regulatory submissions, it added. As per the deal, Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights, Lupin Ltd said. Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin's biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings, it added. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) among others. 'This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients," Lupin President EMEA and Emerging Markets Thierry Volle said. Shares of the company were trading marginally up at Rs 1,946.30 apiece on BSE. PTI MSS MSS ANU ANU view comments First Published: August 12, 2025, 13:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Upturn
12-08-2025
- Business
- Business Upturn
Lupin partners with Sandoz to commercialize Ranibizumab biosimilar in multiple global markets
By Aditya Bhagchandani Published on August 12, 2025, 11:08 IST Lupin Limited announced on August 12 that it has entered into a licensing and commercialization agreement with Switzerland-based Sandoz Group AG for its biosimilar Ranibizumab. The deal covers multiple regions, including the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Under the agreement, Lupin will handle manufacturing and regulatory submissions, while Sandoz will oversee commercialization. Sandoz will hold exclusive marketing rights in most designated markets, except for France, Australia, Vietnam, and Malaysia, where rights will be semi-exclusive. In a separate arrangement, Sandoz will acquire sole commercialization rights for Canada. Ranibizumab is a monoclonal antibody fragment that binds to and inhibits VEGF-A, used in treating conditions such as Neovascular (Wet) Age-Related Macular Degeneration, Diabetic Macular Edema, Proliferative Diabetic Retinopathy, and other retinal diseases. Thierry Volle, President EMEA and Emerging Markets at Lupin, said the partnership aligns with both companies' vision to expand global access to advanced biologic therapies and improve outcomes for underserved patients. Lupin, a global pharmaceutical leader headquartered in Mumbai, has a presence in over 100 markets, with 15 manufacturing sites and seven research centers worldwide. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
